DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations
Open Access
- 19 June 2021
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 69, 103446
- https://doi.org/10.1016/j.ebiom.2021.103446
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Model-based gene set analysis for BioconductorBioinformatics, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Breast Cancer Subtypes and the Risk of Local and Regional RelapseJournal of Clinical Oncology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Logistic RegressionCirculation, 2008
- Cancer risks among BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003